Filip Stanicic, PhD(c)

HEOR Partner
ZRx Outcomes Research Inc.
Mississauga, Ontario

Filip Stanicic, MSc, is a HEOR Partner at ZRx Outcomes Research Inc. Filip is responsible for extracting quantitative and qualitative data from healthcare databases and published sources of evidence. Furthermore, his tasks include defining future research questions, planning and executing data analyses within the scope of real-world evidence. Filip is currently focused on research in addiction, opioid dependence, pain management, and
medical device decision modelling, in which he employs the evidence derived from complex insurance claims and EHR databases to improve medical decision-making.

Presentation(s):

• P-016 - (Poster #16) A Retrospective US Commercial Claims Analysis Comparing the Safety Profile of Belbuca and Oral Schedule II Long-Acting Opioids Used for Chronic Low-Back Pain Treatment among Patients Previously Treated with Short-Acting Opioids

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-011 - (Poster #11) Economic Burden of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-017 - (Poster #17) Opioid Use Disorder Outcomes of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-010 - (Poster #10) Treatment Characteristics and Safety of Belbuca, Buprenorphine Patch, and Oral Schedule II Opioid Treatments among Chronic Low Back Pain Patients without Positive History of Opioid-Use Disorder: A Retrospective US Commercial Claims Analysis

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-015 - (Poster #15) Treatment Characteristics of Chronic Low Back Pain Patients Transitioned from Oral Schedule II Short-Acting Opioids to Belbuca or Oral Schedule II Long-Acting Opioids: A Retrospective US Commercial Claims Analysis

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST